Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

SODIUM ACETATE INJECTION, USP 328 MG

SODIUM ACETATE : 328 MG · DIN 02139529 · FRESENIUS KABI CANADA LTD

Health Canada status: MARKETED

What is SODIUM ACETATE INJECTION, USP?

SODIUM ACETATE INJECTION, USP 328 MG contains SODIUM ACETATE : 328 MG. It is listed in the Health Canada Drug Product Database under DIN 02139529, held by FRESENIUS KABI CANADA LTD, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 26-Apr-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is SODIUM ACETATE INJECTION, USP used for?

Source of sodium to prevent or correct hyponatremia in patients with restricted or no oral intake; additive for preparing specific intravenous fluid formulas.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02139529
Brand nameSODIUM ACETATE INJECTION, USP
Generic / active ingredientSODIUM ACETATE : 328 MG
ManufacturerFRESENIUS KABI CANADA LTD
Strength328 MG
Dosage formSOLUTION
Route of administrationINTRAVENOUS
ScheduleEthical
ATC codeB05XA08 SODIUM ACETATE
AHFS class40:12.00
BiosimilarNo
Health Canada statusMARKETED
Status date26-Apr-2016
Original market date1996-08-14 00:00:00

How is it administered?

Administered intravenously only after dilution. Dose and rate depend on individual patient needs; serum sodium should be monitored as a guide. Not for direct infusion.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store at 15 °C to 30 °C. Do not freeze. Discard Pharmacy Bulk Package unused portion within 24 hours after entry.

How is it supplied?

50 mL single-dose vials and 100 mL Maxivial Pharmacy Bulk Packages; supplied in boxes of 25.

Contraindications

Contraindicated in patients with hypernatremia or fluid retention.

Warnings and precautions

Must be diluted before use. Risk of sodium overload, water retention, and aluminum toxicity (especially in neonates or renal impairment). Avoid rapid infusion.

Is SODIUM ACETATE in shortage in Canada?

A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.

Check availability for SODIUM ACETATE INJECTION, USP

What can be used instead?

Other Canadian products sharing ATC code B05XA08 SODIUM ACETATE. 2 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
SODIUM ACETATE INJECTION USP328 MGSolutionOMEGA LABORATORIES LIMITEDMARKETEDDIN 02181746
16.4% SODIUM ACETATE INJECTION, USP16.4 %SOLUTIONBAXTER CORPORATIONCANCELLED POST MARKETDIN 02247204
SODIUM ACETATE INJ 328MG/ML USP328 MGLIQUIDSABEX INCCANCELLED POST MARKETDIN 00780642
SODIUM ACETATE INJ 328MG/ML USP328 MGLIQUIDLYPHOMED, DIVISION OF FUJISAWA CANADA INC.CANCELLED POST MARKETDIN 01944843

Who else supplies SODIUM ACETATE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. SODIUM ACETATE appears in 5432 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for SODIUM ACETATE INJECTION, USP

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 02139529. Last reviewed 2026-09-09. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.